IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 heart pump can significantly enhance quality of life and reduce adverse events.
Here's Why You Should Retain CVS Health (CVS) in Your Portfolio
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on solid first-quarter performance and growth in digital health services.
Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $560.35, moving +0.36% from the previous trading session.
STERIS (STE) Expands Product Suite With New Acquisition
by Zacks Equity Research
STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm
by Zacks Equity Research
The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.
Why Is Idexx (IDXX) Up 3.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why IDEXX (IDXX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX (IDXX).
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 36.63% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Stock Moves -0.66%: What You Should Know
by Zacks Equity Research
In the latest trading session, Idexx Laboratories (IDXX) closed at $548.99, marking a -0.66% move from the previous day.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite
by Zacks Equity Research
Zimmer Biomet's (ZBH) latest portfolio enhancement is aimed at improving patient outcome throughout the entire treatment process.
Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays
by Zacks Equity Research
Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal second-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
Reasons to Hold on to Syneos Health (SYNH) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
by Zacks Equity Research
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
by Zacks Equity Research
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
Here's Why You Should Retain Henry Schein (HSIC) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on robust sales of PPE and COVID-19-related products.